News from biotrends research group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 14, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

U.S. Physicians Report Diabetic Nephropathy as the Renal Condition with the Highest Unmet Need for Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Mar 13, 2013, 11:30 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces the...

Mar 06, 2013, 09:00 ET
Mar 05, 2013, 09:30 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Gastroenterologists Indicate They Are Increasingly Using Biologics to Treat Patients with Crohn's Disease in Remission than They Were One Year Ago, According to a Recent BioTrends Report

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, although...

Feb 07, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized...

Feb 05, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the...

Jan 16, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Even with Aubagio's Recent Launch, the Impact of Gilenya and Tysabri Label Revisions Continue to Dominate Changes in the U.S. Multiple Sclerosis Market, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...

Jan 14, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

U.S. Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs; Physicians Find High Interest in HIF Inhibitors SFP, Zerenex and CTAP101

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds declining...

Jan 09, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Oral Formulation Drives Early Trial of Genzyme's Aubagio, Although Safety Concerns are Identified as Obstacles at One Month Post-Launch, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 16...

Jan 08, 2013, 08:00 ET

Although Usage Remains Low Six Months Post-Launch, U.S. Nephrologists Continue to Report High Anticipated Future Use of Omontys

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings...

Jan 07, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Recent Eylea Growth Appears to be Coming from Expanded Uptake Among Prescribers Rather than from Initial Trial Among Late Adopters, According to a Recent BioTrends Report

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, after...

Dec 21, 2010, 10:15 ET
Dec 21, 2010, 10:15 ET

European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends

BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line...

Dec 20, 2010, 10:00 ET

Newer Anti-TNF Alpha Agents Simponi and Cimzia Appear To Be Making In-Roads Into First Line Biologic Position in Rheumatoid Arthritis, According to a New Report by BioTrends

In its recently released annual 2010 update, ChartTrends®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer...

Dec 13, 2010, 10:45 ET

Acorda's Ampyra Sustains High Levels of Interest Seven Months After Launch With Favorable Future Share Projections

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that on most metrics, perceptions of Acorda's Ampyra, the first...

Dec 13, 2010, 10:45 ET

With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch

BioTrends Research Group, Inc. finds that with the introduction of Novartis' Gilenya, the first oral disease-modifying agent (DMA) for the...

Dec 08, 2010, 08:00 ET

TreatmentTrends®: European Gout Study Highlights Current Treatment Patterns and Unmet Need For New Gout Therapies Among Rheumatologists

BioTrends Research Group, Inc. finds that although Allopurinol remains the gold standard uric acid lowering (UAL) therapy for gout in the European...

Dec 06, 2010, 08:00 ET

Surveyed Neurologists are Eager to Prescribe Gilenya, the First Oral Disease-Modifying Agent for MS, But Say They are Held Back by Initial Prescribing Obstacles and Potential Safety/Tolerability Concerns

BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by...

Dec 01, 2010, 09:00 ET

TreatmentTrends®: Multiple Sclerosis Study Uncovers Early Impact of Gilenya on Perceptions and Anticipated Use of Products Within the MS Market

BioTrends recently published TreatmentTrends®: Multiple Sclerosis, a syndicated  biannual report that provides a comprehensive view of...

Nov 29, 2010, 12:40 ET

BioTrends Report Characterizes Chronic Kidney Disease Patients Under the Care of a Nephrologist and Identifies Factors That Drive Decisions to Treat Disorders of Bone and Mineral Metabolism

BioTrends Research Group, Inc. released ChartTrends®: Bone and Mineral Metabolism in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual...